{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:28Z","timestamp":1792786108002,"version":"4.5.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CIPHER"},{"DOI":"10.13039\/501100024848","name":"IAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007936","name":"International AIDS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007936","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Health"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT108082AIA"],"award-info":[{"award-number":["WT108082AIA"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hong Kong Jockey Club Global Health Institute","id":[{"id":"https:\/\/ror.org\/015ygrv52","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hong Kong Special Administrative Region"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In a retrospective Nigerian cohort of 33 982 people with HIV-1 initiating or switching to tenofovir, lamivudine, and dolutegravir, virological suppression reached 80%\u201382% among participants with available viral load data and 63%\u201365% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.<\/jats:p>","DOI":"10.1093\/ofid\/ofag549","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:34:37Z","timestamp":1787657677000},"source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Outcomes of Dolutegravir-Based Antiretroviral Therapy in a Large Nigerian Programmatic HIV-1 Cohort, 2017\u20132019"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-8264","authenticated-orcid":false,"given":"Adam","family":"Abdullahi","sequence":"first","affiliation":[{"name":"Takemi Program in International Health, Harvard Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Cambridge Institute of Therapeutic Immunology & Infectious Disease Department of Medicine, , Cambridge ,","place":["UK"]},{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edun","family":"Martin","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5074-2315","authenticated-orcid":false,"given":"Asare","family":"Kwabena","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Wisso Abdullahi","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Musa","family":"Kida","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Immunology, University of Maiduguri Teaching Hospital , Maiduguri ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Osawe","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Onyemata","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-2940","authenticated-orcid":false,"given":"Sani H","family":"Aliyu","sequence":"additional","affiliation":[{"name":"Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhattan","family":"Charurat","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-8958","authenticated-orcid":false,"given":"Fatima-Murtala","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Adamu","sequence":"additional","affiliation":[{"name":"Division of Global HIV & Tuberculosis, U.S. Centers for Disease Control and Prevention , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Omuh","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Efuntoye","sequence":"additional","affiliation":[{"name":"Division of Global HIV & Tuberculosis, U.S. Centers for Disease Control and Prevention , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dakum","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alash\u2019le","family":"Abimiku","sequence":"additional","affiliation":[{"name":"International Research Centre of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Cambridge Institute of Therapeutic Immunology & Infectious Disease Department of Medicine, , Cambridge ,","place":["UK"]},{"name":"Africa Health Research Institute , Durban ,","place":["South Africa"]},{"name":"The Hong Kong Jockey Club Global Health Institute (HKJCGHI) , Hong Kong Special Administrative Region ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026091805322686100_ofag549-B1","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3018(17)30086-3","article-title":"Improved life expectancy of people living with HIV: who is left behind?","volume":"4","author":"Katz","year":"2017","journal-title":"Lancet HIV"},{"key":"2026091805322686100_ofag549-B2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S2666-7568(22)00063-0","article-title":"Life expectancy of people with HIV on long-term antiretroviral therapy in Europe and North America: a cohort study","volume":"3","author":"Trickey","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"2026091805322686100_ofag549-B3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026091805322686100_ofag549-B4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Gregson","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026091805322686100_ofag549-B5","doi-asserted-by":"crossref","first-page":"e1001810","DOI":"10.1371\/journal.pmed.1001810","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med"},{"key":"2026091805322686100_ofag549-B6","volume-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"World Health Organization","year":"2019"},{"key":"2026091805322686100_ofag549-B7","volume-title":"Understanding measures of progress towards the 95\u201395\u201395 HIV testing, treatment and viral suppression targets","author":"UNAIDS","year":"2023"},{"key":"2026091805322686100_ofag549-B8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/hiv.13189","article-title":"Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study)","volume":"23","author":"Brown","year":"2022","journal-title":"HIV Med"},{"key":"2026091805322686100_ofag549-B9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/ciad390","article-title":"Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL human immunodeficiency virus cohort in Lesotho","volume":"77","author":"Tschumi","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026091805322686100_ofag549-B10","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study","volume":"9","author":"Schramm","year":"2022","journal-title":"Lancet HIV"},{"key":"2026091805322686100_ofag549-B11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAI.0000000000003065","article-title":"Brief report: virologic impact of the dolutegravir transition: prospective results from the multinational African cohort study","volume":"91","author":"Allahna","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026091805322686100_ofag549-B12","doi-asserted-by":"crossref","first-page":"e2540","DOI":"10.1002\/rmv.2540","article-title":"Prevalence and factors associated with viral non-suppression in people living with HIV receiving antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis","volume":"34","author":"Mosha","year":"2024","journal-title":"Rev Med Virol"},{"key":"2026091805322686100_ofag549-B13","doi-asserted-by":"crossref","first-page":"100231","DOI":"10.1016\/j.eclinm.2019.12.001","article-title":"Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa","volume":"18","author":"Villa","year":"2020","journal-title":"eClinicalMedicine"},{"key":"2026091805322686100_ofag549-B14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5334\/aogh.3226","article-title":"The burden of HIV, hepatitis B and hepatitis C by armed conflict setting: the Nigeria AIDS indicator and impact survey, 2018","volume":"87","author":"Aliyu","year":"2021","journal-title":"Ann Glob Health"},{"key":"2026091805322686100_ofag549-B15","doi-asserted-by":"crossref","first-page":"102098","DOI":"10.1016\/j.eclinm.2023.102098","article-title":"Estimation of HIV prevalence and burden in Nigeria: a Bayesian predictive modelling study","volume":"62","author":"Onovo","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026091805322686100_ofag549-B16","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1038\/s41467-020-19801-x","article-title":"Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase","volume":"11","author":"Siedner","year":"2020","journal-title":"Nat Commun"},{"key":"2026091805322686100_ofag549-B17","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/jac\/dkad195","article-title":"Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort","volume":"78","author":"Abdullahi","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026091805322686100_ofag549-B18","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/jac\/dkz264","article-title":"An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy","volume":"74","author":"Geretti","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026091805322686100_ofag549-B19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12985-023-02245-2","article-title":"HIV viral suppression at different thresholds and duration of treatment in the dolutegravir treatment era in Sierra Leone: a nationwide survey","volume":"20","author":"Song","year":"2023","journal-title":"Virol J"},{"key":"2026091805322686100_ofag549-B20","doi-asserted-by":"crossref","first-page":"1482348","DOI":"10.3389\/fmicb.2024.1482348","article-title":"Low prevalence of archived integrase strand transfer inhibitors resistance associated mutations in Botswana before the roll out of dolutegravir based first line antiretroviral therapy","volume":"15","author":"Maruapula","year":"2024","journal-title":"Front Microbiol"},{"key":"2026091805322686100_ofag549-B21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jac\/dkad386","article-title":"A detailed characterization of drug resistance during darunavir\/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance","volume":"79","author":"Abdullahi","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag549\/70828229\/ofag549.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag549\/70828229\/ofag549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag549\/70828229\/ofag549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:33:24Z","timestamp":1789724004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag549\/8772353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag549","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,28]]},"article-number":"ofag549"}}